Business Roundtable
Commercialization Readiness - Sales & Marketing Compliance
Monday, February 12, 2007
9:30 AM
Duke of Windsor
With an increasing number of biotechnology companies facing decisions regarding commercialization, the decision of whether to build a sales force internally or utilize a third party could have both short- and long-term implications to a product?s market penetration and financial return. Regardless, as evidenced by a number of ongoing investigations and high profile settlements with the Office of Inspector General and states? Attorneys General, increased regulatory oversight is a reality. This environment makes it more important than ever for companies to focus on building in compliance activities from the start, including issues such as appropriate communications around new products and new indications, payments to doctors, and capturing ?best price? for purposes of calculating government rebates. The panel will explore the regulatory landscape including the foundational elements of an effective compliance function.
Moderators
- Ted Acosta, JD; National Leader, Health Sciences, Investigative & Dispute Services, Ernst & Young, LLP
Panelists
- Garry O'Grady; Senior Vice President, Sales Practice, Campbell Alliance
- Robert J. Perez; Senior Vice President, Commercial Operations, Cubist Pharmaceuticals, Inc.
- Elizabeth Lewis; VP, Commercial Law, Millennium Pharmaceuticals
- Natasha Leskovsek; Special Counsel, Heller Ehrman LLP